|
|
||||||||
The costs of mefloquine, chloroquine, doxycycline, primaquine, and atovaquone/proguanil are calculated for various durations of exposure to malaria. The cost is included for detecting glucose 6-phosphate dehydrogenase (G6PD) deficiency before administering primaquine for primary or terminal prophylaxis. For durations of exposure ranging from 3 to 730 days, if no terminal prophylaxis is given, doxycycline (generic) is the least expensive regimen. Compared with doxycycline hyclate, chloroquine costs three to four times more, and primaquine, after screening for G6PD, costs about eight times more. Atovaquone/proguanil is less expensive than mefloquine for a 3-day exposure, but more expensive for 7 or more days. When terminal chemoprophylaxis with primaquine for 14 days is used in addition to doxycycline, mefloquine, chloroquine, or atovaquone/proguanil, primaquine alone is the least expensive regimen for exposures of < 10 days. Thereafter, doxycycline plus 14 days of primaquine is most economical. For subsequent exposures when G6PD status is already known, primaquine alone is the least expensive regimen for up to 9 days of exposure, but doxycycline is less expensive thereafter. In general, generic doxycycline hyclate is the least expensive regimen. Primaquine alone is economically attractive. Mefloquine, doxycyline monohydrate, and atovaquone/proguanil, the most expensive regimens, are similar in cost for a 7-day exposure, but thereafter, atovaquone/proguanil is much more expensive.
Received December 19, 2005. Accepted for publication April 30, 2006.
Acknowledgments: The author gratefully acknowledges helpful comments from Capt. Monica Parise.
Disclaimer: The opinions expressed herein are those of the author and are not to be construed as official and do not necessarily represent the views or official policies of the Department of State or U.S. Government.
Address correspondence to Joe P. Bryan, 1421 Mayflower Drive, McLean, VA 22101. E-mail: joe.p.bryan{at}earthlink.net
Authors address: Joe P. Bryan, 1421 Mayflower Dr., McLean, VA 22101, E-mail: joe.p.bryan{at}earthlink.net.
This article has been cited by other articles:
![]() |
H. Nakato, R. Vivancos, and P. R. Hunter A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria J. Antimicrob. Chemother., November 1, 2007; 60(5): 929 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. BOGGILD, M. E. PARISE, L. S. LEWIS, and K. C. KAIN ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II) Am J Trop Med Hyg, February 1, 2007; 76(2): 208 - 223. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. HILL, J. K. BAIRD, M. E. PARISE, L. S. LEWIS, E. T. RYAN, and A. J. MAGILL PRIMAQUINE: REPORT FROM CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS I. Am J Trop Med Hyg, September 1, 2006; 75(3): 402 - 415. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | SEARCH RESULT |